ENDPD- SLOWING DOWN PARKINSON’S DISEASE PATHOLOGICAL PROGRESSION.

Patients and society expect that technical and scientific advances can provide novel improved answers to address unmet medical needs.

Parkinson's disease (PD) is the 2nd most prevalent neurodegenerative disorder in the world, with profound economic and social impacts. The absence of preventive therapies to tackle PD, requires the development of new therapeutic strategies.

For Pharma companies, aiming to develop molecules for Parkinson Disease (PD) and other neurologic disorders, Fastprinciple is developing a new drug candidate, to be used as a future therapy to slow-down PD progression.

Unlike alternative solutions (such as the ones commercialized by Bial, Acadia Pharmaceuticals, Abbvie, Lilly, and others), which target the symptoms, we expect to slow down the disease progression, increasing current therapies’ effectiveness overtime. PD affects more than 10 million people globally and has an enormous social and economic burden.

Current treatments manage the symptoms of the disease but do not offer the patients the possibility of a cure.

Unfortunately, as the disease progress to higher debilitating stage, the patient stops responding to the current symptomatic therapies, ending without therapeutic options.

We have identified a molecule that with the company’s patented reformulation technology will improve the drug efficacy and slowdown the disease progression of the disease.

The current proposal aims to establish FastPrinciple’s Strategic monetization plan, by securing IP strategy and to ameliorate our business and exploitation plan.